Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers

Park Ji Hyun; Kang Myung Joo; Ahn Jin-Hee; Kim Jeong Eun; Jung Kyung Hae; Gong Gyungyub; Lee Hee Jin; Son Byung-Ho; Ahn Sei-Hyun; Kim Hak-Hee; Shin Hee Jung; Moon Dae-Hyuk; Kim Sung-Bae

首页> 外文期刊>Cancer chemotherapy and pharmacology. >Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers

【24h】

Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers

机译：新辅助来曲唑和拉帕替尼在亚洲绝经后患有雌激素受体（ER）和人表皮生长因子受体2（HER2）阳性乳腺癌的女性的II期试验[Neo-ALL-IN]：强调新辅助治疗后TILs，ER表达的变化和FES-PET作为潜在的重要生物标志物

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose Neo-ALL-IN (NCT 01275859) is a single-center, phase II study aimed to evaluate the efficacy and safety profiles of neoadjuvant letrozole plus lapatinib, as well as potential biomarkers, in postmenopausal women with ERand HER2-positive (ER+HER2+) breast cancer.

机译：目的Neo-ALL-IN（NCT 01275859）是一项单中心II期研究，旨在评估新辅助来曲唑加拉帕替尼以及具有ER和HER2阳性（ER + HER2 +）乳腺癌。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2016年第4期|共11页
作者
Park Ji Hyun; Kang Myung Joo; Ahn Jin-Hee; Kim Jeong Eun; Jung Kyung Hae; Gong Gyungyub; Lee Hee Jin; Son Byung-Ho; Ahn Sei-Hyun; Kim Hak-Hee; Shin Hee Jung; Moon Dae-Hyuk; Kim Sung-Bae;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Neoadjuvant; Lapatinib; Letrozole; Postmenopausal; FES-PET; TILs; Breast cancer;

机译：新辅助药;拉帕替尼;来曲唑;绝经后;FES-PET;TILs;乳腺癌;

相似文献

外文文献
中文文献
专利

1. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers [J] . Park Ji Hyun, Kang Myung Joo, Ahn Jin-Hee, Cancer chemotherapy and pharmacology. . 2016,第4期

机译：新辅助来曲唑和拉帕替尼在亚洲绝经后患有雌激素受体（ER）和人表皮生长因子受体2（HER2）阳性乳腺癌的女性的II期试验[Neo-ALL-IN]：强调新辅助治疗后TILs，ER表达的变化和FES-PET作为潜在的重要生物标志物
2. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. [J] . Valentina Guarneri, Daniele Giulio Generali, Antonio Frassoldati, Journal of Clinical Oncology . 2014,第10期

机译：双盲，安慰剂控制，多中心，随机，阶段IIB Neoadjuvant研究Letrozole-lapatinib在绝经后激素受体阳性，人表皮生长因子受体2阴性，可操作的乳腺癌。
3. BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTORPOSITIVE (ER plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC) [J] . Bachelot Thomas, Villanueva Cristian, Royce Melanie, The Breast : . 2015,第Suppla3期

机译：BOLERO-4：第2阶段，开放式，多中心，单臂试验，研究了绝经后患者（PTS）和雌激素受体阳性（ER + ），人类表皮生长因子受体2-阴性（HER2-）转移性或局部晚期无法治疗的乳腺癌（BC）
4. Immunohistochemistry applications in breast carcinoma: The Hypoxia Inducible Factor lα, Estrogen Receptor, Progesterone Receptor and HER2 expression before and after neoadjuvant chemotherapy [C] . Zuofeng Zhang, Yunai Liang, Chunhua Zhang, Technical Congress on Resources, Environment and Engineering . 2016

机译：免疫组织化学在乳腺癌中的应用：缺氧诱导因子Lα，雌激素受体，孕酮受体和Neoadjuvant化疗前后和Her2表达
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. Estrogen Receptor Progesterone Receptor Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer [O] . Richard S. Finn, Michael F. Press, Judy Dering, -1

机译：紫杉醇与拉帕替尼或安慰剂作为HER2阴性或未知转移性乳腺癌的一线治疗的随机试验雌激素受体孕激素受体人表皮生长因子受体2（HER2）和表皮生长因子受体的表达及拉帕替尼的获益
7. Double-blind, placebo-controlled, multicenter, randomized, phase IIB neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer [O] . Guarneri Valentina, Generali Daniele, Frassoldati Antonio, 2014

机译：来曲唑-拉帕替尼治疗绝经后激素受体阳性，人表皮生长因子受体2-阴性，可手术的乳腺癌的双盲，安慰剂对照，随机，IIB期新辅助研究

摘要

著录项

相似文献

相关主题

期刊订阅